BRIDGEBIO ONCOLOGY THERAPEUTICS, INC. — Net Income by Fiscal Year
3 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/12d36a21-4725-42b2-8a2b-0c5f71df6d14/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-134.0M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-093997 |
| FY 2024 | $-74.3M | 2024-01-01 – 2024-12-31 | evidence 0001193125-26-093997 |
| FY 2023 | $-41.7k | 2023-01-01 – 2023-12-31 | evidence 0001213900-25-022387 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
BRIDGEBIO ONCOLOGY THERAPEUTICS, INC. — all facts · Operating Income